{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:02:09Z","timestamp":1793692929966,"version":"4.5.1"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007427","name":"MPN Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007427","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1038\/s41375-026-03103-0","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:05:26Z","timestamp":1788271526000},"page":"2395-2405","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Defining and predicting disease progression in myeloproliferative neoplasms: a proposed biomarker-driven approach"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-6368","authenticated-orcid":false,"given":"Raajit K.","family":"Rampal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Winneker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kuykendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1798-9658","authenticated-orcid":false,"given":"Laura C.","family":"Michaelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1881-3670","authenticated-orcid":false,"given":"Ghaith","family":"Abu-Zeinah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1011-8171","authenticated-orcid":false,"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan Philipp","family":"Bewersdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5050-1223","authenticated-orcid":false,"given":"Zi Yun","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0199-9333","authenticated-orcid":false,"given":"Gabriella","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8590-6175","authenticated-orcid":false,"given":"Bridget","family":"Marcellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4004-7060","authenticated-orcid":false,"given":"Linda","family":"Resar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9525-143X","authenticated-orcid":false,"given":"Joseph","family":"Scandura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0296-8686","authenticated-orcid":false,"given":"Anand","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-1309","authenticated-orcid":false,"given":"Aaron","family":"Gerds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Mayack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2438-1955","authenticated-orcid":false,"given":"Florian H.","family":"Heidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"3103_CR1","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1158\/2159-8290.CD-25-1784","volume":"15","author":"N Mai","year":"2025","unstructured":"Mai N, Fernandez N, Drilon A, Chakravarty D. Precision oncology: 2025 in review. Cancer Discov. 2025;15:2414\u201321.","journal-title":"Cancer Discov"},{"key":"3103_CR2","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","volume":"28","author":"J Mateo","year":"2022","unstructured":"Mateo J, Steuten L, Aftimos P, Andre F, Davies M, Garralda E, et al. Delivering precision oncology to patients with cancer. Nat Med. 2022;28:658\u201365.","journal-title":"Nat Med"},{"key":"3103_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","volume":"40","author":"A Letai","year":"2022","unstructured":"Letai A, Bhola P, Welm AL. Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell. 2022;40:26\u201335.","journal-title":"Cancer Cell"},{"key":"3103_CR4","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1200\/JCO.19.00945","volume":"37","author":"F Andre","year":"2019","unstructured":"Andre F, Ismaila N, Henry NL, Somerfield MR, Bast RC, Barlow W, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update\u2014integration of results from TAILORx. J Clin Oncol. 2019;37:1956\u201364.","journal-title":"J Clin Oncol"},{"key":"3103_CR5","first-page":"393","volume":"9","author":"TP McVeigh","year":"2017","unstructured":"McVeigh TP, Kerin MJ. Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer. Breast Cancer. 2017;9:393\u2013400.","journal-title":"Breast Cancer"},{"key":"3103_CR6","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1038\/s41375-025-02654-y","volume":"39","author":"S Zanwar","year":"2025","unstructured":"Zanwar S, Rajkumar SV. Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders. Leukemia. 2025;39:2610\u20137.","journal-title":"Leukemia"},{"key":"3103_CR7","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood. 2005;106:812\u20137.","journal-title":"Blood"},{"key":"3103_CR8","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ajh.26915","volume":"98","author":"AA Mangaonkar","year":"2023","unstructured":"Mangaonkar AA, Patnaik MM. Clonal hematopoiesis of indeterminate potential and clonal cytopenias of undetermined significance: 2023 update on clinical associations and management recommendations. Am J Hematol. 2023;98:951\u201364.","journal-title":"Am J Hematol"},{"key":"3103_CR9","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","volume":"559","author":"S Abelson","year":"2018","unstructured":"Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559:400\u20134.","journal-title":"Nature"},{"key":"3103_CR10","doi-asserted-by":"publisher","unstructured":"Weeks LD, Niroula A, Neuberg D, Wong W, Lindsley RC, Luskin M, et al. Prediction of risk for myeloid malignancy in clonal hematopoiesis. NEJM Evid. 2023;2. https:\/\/doi.org\/10.1056\/evidoa2200310.","DOI":"10.1056\/evidoa2200310"},{"key":"3103_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.blre.2016.06.001","volume":"30","author":"T Barbui","year":"2016","unstructured":"Barbui T, Thiele J, Gisslinger H, Finazzi G, Vannucchi AM, Tefferi A. The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances. Blood Rev. 2016;30:453\u20139.","journal-title":"Blood Rev"},{"key":"3103_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","volume":"1","author":"A Tefferi","year":"2015","unstructured":"Tefferi A, Pardanani A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 2015;1:97\u2013105.","journal-title":"JAMA Oncol"},{"key":"3103_CR13","doi-asserted-by":"publisher","first-page":"6224","DOI":"10.1073\/pnas.0601462103","volume":"103","author":"CH Jamieson","year":"2006","unstructured":"Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci USA. 2006;103:6224\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3103_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.hoc.2020.12.008","volume":"35","author":"T Jain","year":"2021","unstructured":"Jain T, Rampal RK. Accelerated and blast phase myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2021;35:325\u201335.","journal-title":"Hematol Oncol Clin North Am"},{"key":"3103_CR15","doi-asserted-by":"crossref","unstructured":"Baumeister J, Chatain N, Sofias AM, Lammers T, Koschmieder S. Progression of myeloproliferative neoplasms (MPN): diagnostic and therapeutic perspectives. Cells. 2021;10:3551.","DOI":"10.3390\/cells10123551"},{"key":"3103_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000530940","volume":"91","author":"C Faria","year":"2024","unstructured":"Faria C, Tzankov A. Progression in myeloid neoplasms: beyond the myeloblast. Pathobiology. 2024;91:55\u201375.","journal-title":"Pathobiology"},{"key":"3103_CR17","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1182\/blood.2023021218","volume":"142","author":"N Kroger","year":"2023","unstructured":"Kroger N, Wolschke C, Gagelmann N. How I treat transplant-eligible patients with myelofibrosis. Blood. 2023;142:1683\u201396.","journal-title":"Blood"},{"key":"3103_CR18","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507\u201313.","journal-title":"Blood"},{"key":"3103_CR19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, et al. Primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (post-PV MF), post-essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Leuk Res. 2007;31:737\u201340.","journal-title":"Leuk Res"},{"key":"3103_CR20","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200\u201328.","journal-title":"Blood"},{"key":"3103_CR21","doi-asserted-by":"crossref","unstructured":"Barbui T, Thiele J, Alvarez-Larran A, Rambaldi A, Vannucchi AM, Tefferi A. From essential thrombocythemia to polycythemia vera (ET-2-PV): rationale and design of a multicenter ELN study. Ann Hematol. 2026;105:158.","DOI":"10.1007\/s00277-026-06898-1"},{"key":"3103_CR22","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1038\/leu.2014.328","volume":"29","author":"T Barbui","year":"2015","unstructured":"Barbui T, Thiele J, Carobbio A, Vannucchi AM, Tefferi A. The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis. Leukemia. 2015;29:992\u20133.","journal-title":"Leukemia"},{"key":"3103_CR23","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387\u201397.","journal-title":"Cancer Cell"},{"key":"3103_CR24","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1182\/blood.2022017416","volume":"141","author":"J How","year":"2023","unstructured":"How J, Garcia JS, Mullally A. Biology and therapeutic targeting of molecular mechanisms in MPNs. Blood. 2023;141:1922\u201333.","journal-title":"Blood"},{"key":"3103_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00968-7","volume":"14","author":"GG Loscocco","year":"2024","unstructured":"Loscocco GG, Gesullo F, Capecchi G, Atanasio A, Maccari C, Mannelli F, et al. One thousand patients with essential thrombocythemia: the Florence-CRIMM experience. Blood Cancer J. 2024;14:10.","journal-title":"Blood Cancer J"},{"key":"3103_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00972-x","volume":"14","author":"N Gangat","year":"2024","unstructured":"Gangat N, Karrar O, Al-Kali A, Begna KH, Elliott MA, Wolanskyj-Spinner AP, et al. One thousand patients with essential thrombocythemia: the Mayo Clinic experience. Blood Cancer J. 2024;14:11.","journal-title":"Blood Cancer J"},{"key":"3103_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01079-7","volume":"14","author":"G Abu-Zeinah","year":"2024","unstructured":"Abu-Zeinah G, Erdos K, Lee N, Lebbe A, Bouhali I, Khalid M, et al. Are thrombosis, progression, and survival in ET predictable? Blood Cancer J. 2024;14:103.","journal-title":"Blood Cancer J"},{"key":"3103_CR28","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","volume":"120","author":"F Passamonti","year":"2012","unstructured":"Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120:1197\u2013201.","journal-title":"Blood"},{"key":"3103_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.94","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.","journal-title":"Blood Cancer J"},{"key":"3103_CR30","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1002\/ajh.27079","volume":"98","author":"A Tefferi","year":"2023","unstructured":"Tefferi A, Loscocco GG, Farrukh F, Szuber N, Mannelli F, Pardanani A, et al. A globally applicable \u201ctriple A\u201d risk model for essential thrombocythemia based on age, absolute neutrophil count, and absolute lymphocyte count. Am J Hematol. 2023;98:1829\u201337.","journal-title":"Am J Hematol"},{"key":"3103_CR31","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32:1057\u201369.","journal-title":"Leukemia"},{"key":"3103_CR32","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41375-021-01447-3","volume":"36","author":"G Abu-Zeinah","year":"2022","unstructured":"Abu-Zeinah G, Silver RT, Abu-Zeinah K, Scandura JM. Normal life expectancy for polycythemia vera (PV) patients is possible. Leukemia. 2022;36:569\u201372.","journal-title":"Leukemia"},{"key":"3103_CR33","first-page":"3157","volume":"38","author":"M Lucijanic","year":"2018","unstructured":"Lucijanic M, Cicic D, Stoos-Veic T, Pejsa V, Lucijanic J, Fazlic Dzankic A, et al. Elevated neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in myelofibrosis: inflammatory biomarkers or representatives of myeloproliferation itself? Anticancer Res. 2018;38:3157\u201363.","journal-title":"Anticancer Res"},{"key":"3103_CR34","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","volume":"119","author":"SJ Zhang","year":"2012","unstructured":"Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, et al. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcomes. Blood. 2012;119:4480\u20135.","journal-title":"Blood"},{"key":"3103_CR35","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27:1861\u20139.","journal-title":"Leukemia"},{"key":"3103_CR36","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/s41375-018-0347-y","volume":"33","author":"Y Guo","year":"2019","unstructured":"Guo Y, Zhou Y, Yamatomo S, Yang H, Zhang P, Chen S, et al. ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis. Leukemia. 2019;33:1287\u201391.","journal-title":"Leukemia"},{"key":"3103_CR37","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1172\/JCI94516","volume":"128","author":"AS McKenney","year":"2018","unstructured":"McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, et al. JAK2\/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. J Clin Investig. 2018;128:789\u2013804.","journal-title":"J Clin Investig"},{"key":"3103_CR38","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Nicolosi M, Mudireddy M, Lasho TL, Gangat N, Begna KH, et al. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia. 2018;32:1189\u201399.","journal-title":"Leukemia"},{"key":"3103_CR39","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29:1356\u201363.","journal-title":"J Clin Oncol"},{"key":"3103_CR40","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1182\/blood-2023-180240","volume":"142","author":"A Yacoub","year":"2023","unstructured":"Yacoub A. Progression to myelofibrosis in patients with essential thrombocythemia: a real-world analysis from the prospective MOST study. Blood. 2023;142:2433.","journal-title":"Blood"},{"key":"3103_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00994-z","volume":"14","author":"MK Larsen","year":"2024","unstructured":"Larsen MK, Skov V, Kjaer L, Eickhardt-Dalboge CS, Knudsen TA, Kristiansen MH, et al. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms: a Danish longitudinal study. Blood Cancer J. 2024;14:28.","journal-title":"Blood Cancer J"},{"key":"3103_CR42","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1164\/rccm.202210-1941OC","volume":"208","author":"D Montani","year":"2023","unstructured":"Montani D, Thore P, Mignard X, Jais X, Boucly A, Jevnikar M, et al. Clinical phenotype and outcomes of pulmonary hypertension associated with myeloproliferative neoplasms: a population-based study. Am J Respir Crit Care Med. 2023;208:600\u201312.","journal-title":"Am J Respir Crit Care Med"},{"key":"3103_CR43","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12185-022-03454-1","volume":"117","author":"O Leiva","year":"2023","unstructured":"Leiva O, Ren S, Neuberg D, Bhatt A, Jenkins A, Rosovsky R, et al. Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease. Int J Hematol. 2023;117:90\u20139.","journal-title":"Int J Hematol"},{"key":"3103_CR44","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.kint.2023.09.010","volume":"104","author":"T d\u2019Izarny-Gargas","year":"2023","unstructured":"d\u2019Izarny-Gargas T, Isnard P, Boudhabhay I, Buob D, Moktefi A, Linster C, et al. The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms. Kidney Int. 2023;104:1206\u201318.","journal-title":"Kidney Int"},{"key":"3103_CR45","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.leukres.2014.01.014","volume":"38","author":"AS Christensen","year":"2014","unstructured":"Christensen AS, Moller JB, Hasselbalch HC. Chronic kidney disease in patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Res. 2014;38:490\u20135.","journal-title":"Leuk Res"},{"key":"3103_CR46","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1600-0609.2010.01548.x","volume":"86","author":"K Abdulkarim","year":"2011","unstructured":"Abdulkarim K, Ridell B, Johansson P, Kutti J, Safai-Kutti S, Andreasson B. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol. 2011;86:148\u201355.","journal-title":"Eur J Haematol"},{"key":"3103_CR47","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/modpathol.2013.109","volume":"26","author":"L Boiocchi","year":"2013","unstructured":"Boiocchi L, Mathew S, Gianelli U, Iurlo A, Radice T, Barouk-Fox S, et al. Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in the fibrotic stage. Mod Pathol. 2013;26:1577\u201385.","journal-title":"Mod Pathol"},{"key":"3103_CR48","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","volume":"379","author":"J Grinfeld","year":"2018","unstructured":"Grinfeld J, Nangalia J, Baxter EJ, Wedge DC, Angelopoulos N, Cantrill R, et al. Classification and personalized prognosis in myeloproliferative neoplasms. N Engl J Med. 2018;379:1416\u201330.","journal-title":"N Engl J Med"},{"key":"3103_CR49","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/ajh.27609","volume":"100","author":"A Tefferi","year":"2025","unstructured":"Tefferi A, Abdelmagid M, Loscocco GG, Fathima S, Begna KH, Al-Kali A, et al. TP53 mutations in myeloproliferative neoplasms: context-dependent evaluation of prognostic relevance. Am J Hematol. 2025;100:552\u201360.","journal-title":"Am J Hematol"},{"key":"3103_CR50","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/bjh.20187","volume":"207","author":"T Badar","year":"2025","unstructured":"Badar T, Foran JM, Bewersdorf JP, Wang YH, Coltoff A, El Kettani M, et al. Heterogeneity in outcomes of TP53-mutated myeloproliferative neoplasms based on disease phenotype and mutational status. Br J Haematol. 2025;207:683\u20136.","journal-title":"Br J Haematol"},{"key":"3103_CR51","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/ajh.27400","volume":"99","author":"P Guglielmelli","year":"2024","unstructured":"Guglielmelli P, Mora B, Gesullo F, Mannelli F, Loscocco GG, Signori L, et al. Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia. Am J Hematol. 2024;99:1550\u20139.","journal-title":"Am J Hematol"},{"key":"3103_CR52","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1182\/blood.2023023428","volume":"143","author":"P Guglielmelli","year":"2024","unstructured":"Guglielmelli P, Szuber N, Gangat N, Capecchi G, Maccari C, Harnois M, et al. CALR mutation burden in essential thrombocythemia and disease outcome. Blood. 2024;143:1310\u20134.","journal-title":"Blood"},{"key":"3103_CR53","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1182\/hematology.2022000339","volume":"2022","author":"AM Vannucchi","year":"2022","unstructured":"Vannucchi AM, Guglielmelli P. Molecular prognostication in Ph-negative MPNs in 2022. Hematol Am Soc Hematol Educ Program. 2022;2022:225\u201334.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3103_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100713","volume":"42","author":"J Grinfeld","year":"2020","unstructured":"Grinfeld J. Prognostic models in the myeloproliferative neoplasms. Blood Rev. 2020;42:100713.","journal-title":"Blood Rev"},{"key":"3103_CR55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1:21\u201330.","journal-title":"Blood Adv"},{"key":"3103_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1224590","volume":"13","author":"P Sobieralski","year":"2023","unstructured":"Sobieralski P, Wasag B, Leszczynska A, Zuk M, Bieniaszewska M. The molecular profile in patients with polycythemia vera and essential thrombocythemia is dynamic and correlates with disease\u2019s phenotype. Front Oncol. 2023;13:1224590.","journal-title":"Front Oncol"},{"key":"3103_CR57","doi-asserted-by":"publisher","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","volume":"111","author":"R Rampal","year":"2014","unstructured":"Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, et al. Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci USA. 2014;111:E5401\u201310.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3103_CR58","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41586-021-04312-6","volume":"602","author":"N Williams","year":"2022","unstructured":"Williams N, Lee J, Mitchell E, Moore L, Baxter EJ, Hewinson J, et al. Life histories of myeloproliferative neoplasms inferred from phylogenies. Nature. 2022;602:162\u20138.","journal-title":"Nature"},{"key":"3103_CR59","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/s41375-023-01886-0","volume":"37","author":"N Maslah","year":"2023","unstructured":"Maslah N, Benajiba L, Giraudier S, Kiladjian JJ, Cassinat B. Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape. Leukemia. 2023;37:957\u201363.","journal-title":"Leukemia"},{"key":"3103_CR60","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","volume":"110","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840\u20136.","journal-title":"Blood"},{"key":"3103_CR61","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","volume":"21","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21:1952\u20139.","journal-title":"Leukemia"},{"key":"3103_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00581-6","volume":"11","author":"P Guglielmelli","year":"2021","unstructured":"Guglielmelli P, Loscocco GG, Mannarelli C, Rossi E, Mannelli F, Ramundo F, et al. JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis. Blood Cancer J. 2021;11:199.","journal-title":"Blood Cancer J"},{"key":"3103_CR63","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30:431\u20138.","journal-title":"Leukemia"},{"key":"3103_CR64","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/leu.2014.270","volume":"29","author":"X Cabagnols","year":"2015","unstructured":"Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J, et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution. Leukemia. 2015;29:249\u201352.","journal-title":"Leukemia"},{"key":"3103_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100425","volume":"2","author":"Z Shen","year":"2021","unstructured":"Shen Z, Du W, Perkins C, Fechter L, Natu V, Maecker H, et al. Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms. Cell Rep Med. 2021;2:100425.","journal-title":"Cell Rep Med"},{"key":"3103_CR66","doi-asserted-by":"crossref","unstructured":"Beitzen-Heineke A, Muller MA, Xia Y, Luttrell-Williams E, Schlamp F, Voora D, et al. A platelet transcriptomic signature of thromboinflammation predicts cardiovascular risk. JCI Insight. 2025;10:e195824.","DOI":"10.1172\/jci.insight.195824"},{"key":"3103_CR67","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1182\/bloodadvances.2019001379","volume":"4","author":"R Gangaraju","year":"2020","unstructured":"Gangaraju R, Song J, Kim SJ, Tashi T, Reeves BN, Sundar KM, et al. Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia. Blood Adv. 2020;4:1115\u201330.","journal-title":"Blood Adv"},{"key":"3103_CR68","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.hoc.2020.11.003","volume":"35","author":"G Ramanathan","year":"2021","unstructured":"Ramanathan G, Fleischman AG. The microenvironment in myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2021;35:205\u201316.","journal-title":"Hematol Oncol Clin North Am"},{"key":"3103_CR69","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1182\/bloodadvances.2018024018","volume":"2","author":"BK Marcellino","year":"2018","unstructured":"Marcellino BK, Hoffman R, Tripodi J, Lu M, Kosiorek H, Mascarenhas J, et al. Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53. Blood Adv. 2018;2:3581\u20139.","journal-title":"Blood Adv"},{"key":"3103_CR70","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"3103_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0142-z","volume":"8","author":"G Finazzi","year":"2018","unstructured":"Finazzi G, Vannucchi AM, Barbui T. Prefibrotic myelofibrosis: treatment algorithm 2018. Blood Cancer J. 2018;8:104.","journal-title":"Blood Cancer J"},{"key":"3103_CR72","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","volume":"119","author":"T Barbui","year":"2012","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood. 2012;119:2239\u201341.","journal-title":"Blood"},{"key":"3103_CR73","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1182\/blood.2019003347","volume":"135","author":"L Ronner","year":"2020","unstructured":"Ronner L, Podoltsev N, Gotlib J, Heaney ML, Kuykendall AT, O\u2019Connell C, et al. Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis. Blood. 2020;135:1696\u2013703.","journal-title":"Blood"},{"key":"3103_CR74","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/ajh.25644","volume":"95","author":"B Mora","year":"2020","unstructured":"Mora B, Guglielmelli P, Rumi E, Maffioli M, Barraco D, Rambaldi A, et al. Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC group. Am J Hematol. 2020;95:E1\u2013E3.","journal-title":"Am J Hematol"},{"key":"3103_CR75","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/s41375-026-02893-7","volume":"40","author":"A Srisuwananukorn","year":"2026","unstructured":"Srisuwananukorn A, Loscocco GG, Dolezal JM, Kuykendall AT, Santi R, Zhang L, et al. Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images. Leukemia. 2026;40:1018\u201326.","journal-title":"Leukemia"},{"key":"3103_CR76","doi-asserted-by":"publisher","first-page":"5710","DOI":"10.1158\/1078-0432.CCR-18-0163","volume":"24","author":"J Biton","year":"2018","unstructured":"Biton J, Mansuet-Lupo A, Pecuchet N, Alifano M, Ouakrim H, Arrondeau J, et al. TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung adenocarcinoma. Clin Cancer Res. 2018;24:5710\u201323.","journal-title":"Clin Cancer Res"},{"key":"3103_CR77","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1182\/blood.2024024373","volume":"144","author":"ES Reis","year":"2024","unstructured":"Reis ES, Buonpane R, Celik H, Marty C, Lei A, Jobe F, et al. Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN. Blood. 2024;144:2336\u201348.","journal-title":"Blood"},{"key":"3103_CR78","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41591-022-01793-4","volume":"28","author":"N Sousos","year":"2022","unstructured":"Sousos N, Ni Leathlobhair M, Simoglou Karali C, Louka E, Bienz N, Royston D, et al. In utero origin of myelofibrosis presenting in adult monozygotic twins. Nat Med. 2022;28:1207\u201311.","journal-title":"Nat Med"},{"key":"3103_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70137","volume":"9","author":"JJ Kiladjian","year":"2025","unstructured":"Kiladjian JJ, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, et al. Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea\/best available therapy (PROUD-PV\/CONTINUATION-PV). Hemasphere. 2025;9:e70137.","journal-title":"Hemasphere"},{"key":"3103_CR80","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1182\/bloodadvances.2022007128","volume":"6","author":"G Abu-Zeinah","year":"2022","unstructured":"Abu-Zeinah G, Di Giandomenico S, Choi D, Cruz T, Erdos K, Taylor E, et al. Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome. Blood Adv. 2022;6:5477\u201381.","journal-title":"Blood Adv"},{"key":"3103_CR81","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.molcel.2020.04.008","volume":"78","author":"B Psaila","year":"2020","unstructured":"Psaila B, Wang G, Rodriguez-Meira A, Li R, Heuston EF, Murphy L, et al. Single-cell analyses reveal megakaryocyte-biased hematopoiesis in myelofibrosis and identify mutant clone-specific targets. Mol Cell. 2020;78:477\u201392 e8.","journal-title":"Mol Cell"},{"key":"3103_CR82","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.molcel.2019.01.009","volume":"73","author":"A Rodriguez-Meira","year":"2019","unstructured":"Rodriguez-Meira A, Buck G, Clark SA, Povinelli BJ, Alcolea V, Louka E, et al. Unravelling intratumoral heterogeneity through high-sensitivity single-cell mutational analysis and parallel RNA sequencing. Mol Cell. 2019;73:1292\u2013305 e8.","journal-title":"Mol Cell"},{"key":"3103_CR83","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1182\/blood.2021013925","volume":"139","author":"L Li","year":"2022","unstructured":"Li L, Kim JH, Lu W, Williams DM, Kim J, Cope L, et al. HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression. Blood. 2022;139:2797\u2013815.","journal-title":"Blood"},{"key":"3103_CR84","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1182\/blood.2021014465","volume":"139","author":"B Li","year":"2022","unstructured":"Li B, An W, Wang H, Baslan T, Mowla S, Krishnan A, et al. BMP2\/SMAD pathway activation in JAK2\/p53-mutant megakaryocyte\/erythroid progenitors promotes leukemic transformation. Blood. 2022;139:3630\u201346.","journal-title":"Blood"},{"key":"3103_CR85","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/s43018-023-00607-x","volume":"4","author":"E Grockowiak","year":"2023","unstructured":"Grockowiak E, Korn C, Rak J, Lysenko V, Hallou A, Panvini FM, et al. Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms. Nat Cancer. 2023;4:1193\u2013209.","journal-title":"Nat Cancer"},{"key":"3103_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.641613","volume":"11","author":"JL Spivak","year":"2021","unstructured":"Spivak JL, Moliterno AR. The thrombopoietin receptor, MPL, is a therapeutic target of opportunity in MPN. Front Oncol. 2021;11:641613.","journal-title":"Front Oncol"},{"key":"3103_CR87","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41588-023-01638-x","volume":"56","author":"J Guo","year":"2024","unstructured":"Guo J, Walter K, Quiros PM, Gu M, Baxter EJ, Danesh J, et al. Inherited polygenic effects on common hematological traits influence clonal selection on JAK2(V617F) and the development of myeloproliferative neoplasms. Nat Genet. 2024;56:273\u201380.","journal-title":"Nat Genet"},{"key":"3103_CR88","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1182\/blood-2016-10-696005","volume":"129","author":"AJ Mead","year":"2017","unstructured":"Mead AJ, Mullally A. Myeloproliferative neoplasm stem cells. Blood. 2017;129:1607\u201316.","journal-title":"Blood"},{"key":"3103_CR89","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.3324\/haematol.2023.283723","volume":"109","author":"A Hantel","year":"2024","unstructured":"Hantel A, Luskin MR, Khan I, Warner E, Patel AA, Walsh TP, et al. Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia. Haematologica. 2024;109:1046\u201352.","journal-title":"Haematologica"},{"key":"3103_CR90","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1182\/blood.2025030741","volume":"147","author":"A Hantel","year":"2026","unstructured":"Hantel A, Wang Y, Cronin A, Khan I, Abraham I, Eisfeld AK, et al. Impact of modernizing eligibility criteria on enrollment and representation in acute myeloid leukemia clinical trials. Blood. 2026;147:639\u201349.","journal-title":"Blood"},{"key":"3103_CR91","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1038\/leu.2016.374","volume":"31","author":"A Statler","year":"2017","unstructured":"Statler A, Radivoyevitch T, Siebenaller C, Gerds AT, Kalaycio M, Kodish E, et al. The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies. Leukemia. 2017;31:1808\u201315.","journal-title":"Leukemia"},{"key":"3103_CR92","doi-asserted-by":"publisher","DOI":"10.1177\/20406207231177282","volume":"14","author":"HO Ajufo","year":"2023","unstructured":"Ajufo HO, Waksal JA, Mascarenhas JO, Rampal RK. Treating accelerated and blast phase myeloproliferative neoplasms: progress and challenges. Ther Adv Hematol. 2023;14:20406207231177282.","journal-title":"Ther Adv Hematol"},{"key":"3103_CR93","doi-asserted-by":"publisher","first-page":"e862","DOI":"10.1016\/S2352-3026(25)00264-9","volume":"12","author":"R Mesa","year":"2025","unstructured":"Mesa R, Gill H, Zhang L, Jin J, Kirito K, Komatsu N, et al. Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study. Lancet Haematol. 2025;12:e862\u2013e75.","journal-title":"Lancet Haematol"},{"key":"3103_CR94","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1002\/cncr.34205","volume":"128","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju N, Verstovsek S, Mesa R, Gupta V, Garcia JS, Scandura JM, et al. Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer. 2022;128:2420\u201332.","journal-title":"Cancer"},{"key":"3103_CR95","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood.2023021503","volume":"142","author":"JP Bewersdorf","year":"2023","unstructured":"Bewersdorf JP, How J, Masarova L, Bose P, Pemmaraju N, Mascarenhas J, et al. Moving toward disease modification in polycythemia vera. Blood. 2023;142:1859\u201370.","journal-title":"Blood"},{"key":"3103_CR96","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1200\/JCO.22.01935","volume":"41","author":"CN Harrison","year":"2023","unstructured":"Harrison CN, Nangalia J, Boucher R, Jackson A, Yap C, O\u2019Sullivan J, et al. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. J Clin Oncol. 2023;41:3534\u201344.","journal-title":"J Clin Oncol"},{"key":"3103_CR97","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","volume":"27","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418\u201324.","journal-title":"J Clin Oncol"},{"key":"3103_CR98","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.leukres.2014.06.019","volume":"38","author":"BT Huang","year":"2014","unstructured":"Huang BT, Zeng QC, Zhao WH, Li BS, Chen RL. Interferon alpha-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation. Leuk Res. 2014;38:1177\u201383.","journal-title":"Leuk Res"},{"key":"3103_CR99","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","volume":"126","author":"E Verger","year":"2015","unstructured":"Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, et al. Clinical and molecular response to interferon-alpha therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015;126:2585\u201391.","journal-title":"Blood"},{"key":"3103_CR100","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/S2352-3026(17)30030-3","volume":"4","author":"L Masarova","year":"2017","unstructured":"Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, et al. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83-month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017;4:e165\u2013e75.","journal-title":"Lancet Haematol"},{"key":"3103_CR101","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1182\/blood.2022017578","volume":"141","author":"D Luque Paz","year":"2023","unstructured":"Luque Paz D, Kralovics R, Skoda RC. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023;141:1909\u201321.","journal-title":"Blood"},{"key":"3103_CR102","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1182\/hematology.2020000129","volume":"2020","author":"AA Patel","year":"2020","unstructured":"Patel AA, Odenike O. Genomics of MPN progression. Hematol Am Soc Hematol Educ Program. 2020;2020:440\u20139.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3103_CR103","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1016\/S2352-3026(22)00116-8","volume":"9","author":"N Pemmaraju","year":"2022","unstructured":"Pemmaraju N, Garcia JS, Potluri J, Harb JG, Sun Y, Jung P, et al. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. Lancet Haematol. 2022;9:e434\u2013e44.","journal-title":"Lancet Haematol"},{"key":"3103_CR104","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/bjh.16380","volume":"189","author":"A Tefferi","year":"2020","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Coltro G, Finke CM, Loscocco GG, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189:291\u2013302.","journal-title":"Br J Haematol"},{"key":"3103_CR105","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","volume":"36","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Gangat N, Ketterling RP, Pardanani A, et al. MIPSS70+ Version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis. J Clin Oncol. 2018;36:1769\u201370.","journal-title":"J Clin Oncol"},{"key":"3103_CR106","doi-asserted-by":"crossref","unstructured":"Mora B, Palandri F, Guglielmelli P, Kuykendall AT, Maffioli M, Iurlo A, et al. Genomic profiling for decision-making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. Blood. 2026;148:43\u201357.","DOI":"10.1182\/blood.2025031366"},{"key":"3103_CR107","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395\u20138.","journal-title":"Blood"},{"key":"3103_CR108","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ajh.27136","volume":"99","author":"GG Loscocco","year":"2024","unstructured":"Loscocco GG, Rotunno G, Mannelli F, Coltro G, Gesullo F, Pancani F, et al. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70\/plus\/plus v2.0) for primary myelofibrosis. Am J Hematol. 2024;99:68\u201378.","journal-title":"Am J Hematol"},{"key":"3103_CR109","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","volume":"121","author":"G Barosi","year":"2013","unstructured":"Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121:4778\u201381.","journal-title":"Blood"},{"key":"3103_CR110","doi-asserted-by":"publisher","first-page":"e721","DOI":"10.1097\/HS9.0000000000000721","volume":"6","author":"D Tremblay","year":"2022","unstructured":"Tremblay D, Srisuwananukorn A, Ronner L, Podoltsev N, Gotlib J, Heaney ML, et al. European leukemianet response predicts disease progression but not thrombosis in polycythemia vera. Hemasphere. 2022;6:e721.","journal-title":"Hemasphere"},{"key":"3103_CR111","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2017.76.4886","volume":"36","author":"P Guglielmelli","year":"2018","unstructured":"Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. J Clin Oncol. 2018;36:310\u20138.","journal-title":"J Clin Oncol"},{"key":"3103_CR112","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","volume":"32","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Finke CM, Lasho TL, Hanson CA, Ketterling RP, Gangat N, et al. U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions. Leukemia. 2018;32:2274\u20138.","journal-title":"Leukemia"},{"key":"3103_CR113","first-page":"2901","volume":"141","author":"N Gagelmann","year":"2023","unstructured":"Gagelmann N, Badbaran A, Salit RB, Schroeder T, Gurnari C, Pagliuca S, et al. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood. 2023;141:2901\u201311.","journal-title":"Blood"},{"key":"3103_CR114","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.exphem.2007.08.020","volume":"35","author":"P Guglielmelli","year":"2007","unstructured":"Guglielmelli P, Tozzi L, Pancrazzi A, Bogani C, Antonioli E, Ponziani V, et al. MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol. 2007;35:1708\u201318.","journal-title":"Exp Hematol"},{"key":"3103_CR115","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren O, Prior TJ, Masterson T, Heuck C, Bueno OF, Dash AB, et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end- point for multiple myeloma. Blood. 2024;144:359\u201367.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03103-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03103-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03103-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:02:31Z","timestamp":1793109751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03103-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":115,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3103"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03103-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RR: Consulting fees: AbbVie, Blueprint, Bristol Myers Squibb, Morphosys\/Novartis, Sobi, Disc Medicine, Galecto, Incyte, PharmaEssentia, GSK, Kartos, Karyopharm, Stemline, Zentalis, Protagonist, Sumitomo Dainippon, Cogent, OPNA, Merck, Takeda, Meiji, Calrytix, Silence Therapeutics. Research funding: Morphosys\/Novartis, Incyte, Stemline, Zentalis, Ryvu, Biomed Valley Discoveries, Sumitomo Dainippon. DT: receives contracted research funding paid to his institution from Sobi, Sumitomo, Cogent Biosciences, and Gilead, and consulting fees from Sobi, AbbVie, Pharmaessentia, Geron, GSK, and Cogent Biosciences. GH: Consulting\/SAB- GSK, BMS, Incyte, Pharmaessentia, Merck, Cogent, Sobi, Novartis. AAP: Consulting fees from AbbVie, Amgen, Astellas, Jazz, Sobi, and Syndax; Research funding (institutional) from Pfizer, Incyte, Servier, and Sumitomo. GAZ: Consulting fees from PharmaEssentia, Takeda, and Silence Therapeutics. Research funding from PharmaEssentia, SK: research funding from Novartis, Bristol-Myers Squibb, AOP Pharma, Janssen, Geron, and the MPN Research Foundation; advisory board honoraria from Pfizer, Incyte, Ariad, Novartis, AOP Pharma, BMS, Celgene, Geron, Janssen, CTI, Roche, Baxalta, Sanofi, Sierra Oncology, GSK, Abbvie, PharmaEssentia, Protagonist, and MSD; patent for BET inhibitor at RWTH Aachen University; honoraria from Novartis, BMS, Celgene, Geron, Janssen, Pfizer, Incyte, Ariad, Shire, Roche, AOP Pharma, GSK, Abbvie, MPN Hub, iOMEDICO, MSD, and Astra Zeneca; and other financial support (e.g., travel support) from Alexion, Novartis, BMS, Incyte, Ariad, AOP Pharma, Baxalta, CTI, Pfizer, Sanofi, Celgene, Shire, Janssen, Geron, Abbvie, Karthos, Sierra Oncology, Imago Bioscience, GSK, Abbvie, iOMEDICO, Protagonist, and MSD. FHH is a consultant for BMS\/Celgene, AOP, Novartis, CTI, Janssen, AbbVie, GSK, Merck, Kartos, Telios, Silence, Prelude, Takeda, and Sumitomo, and received research funding from Novartis, BMS\/Celgene, and CTI.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}